Table1

 Outward pharmaceutical sales and SSATG derived sales in SEK for biological drugs during the period 2000–03 in Scania (€1 = 9.05 SEK, $1 = SEK 8.5 SEK, May 2003)

2000200120022003Sum 2000–03
For comparison the ratio between pharmaceutical and SSATG sales is also given. The proportion of patients for each diagnosis treated with biological agents as well as the relation (in %) to the estimated total RA population in Scania (0.5% of adult population) during the period 2000–03 according to the SSATG register.
Pharmacy
Etanercept18983353233851022549337334371270102233098
Infliximab13259906271738453761777843080718121132247
Anakinra00138476026230484007808
Adalimumab00039993763999376
Total 32243259 50558947 64495911 84074412 231372529
SSATG
Etanercept24772571253849332852585437028082115711440
Infliximab8368944219708483214642640032834102519052
Anakinra0095043520264402976875
Adalimumab00048468064846806
Total 33141515 47355781 61622715 83934162 226054173
Pharmacy/SSATG cost ratio
Etanercept0.770.920.890.930.88
Infliximab1.581.241.171.081.18
Anakinra1.461.291.35
Adalimumab0.830.83
Total 0.97 1.07 1.05 1.00 1.02
Proportion of adult population treated with biological agents (per 100 000 inhabitants)
RA38.351.461.474.6
Psoriatic arthritis2.33.65.27.3
Other spondarthritis1.12.84.67.6
JCA2.13.13.94.7
Miscellaneous0.21.11.62.3
Total 44.0 62.1 76.6 96.5
Proportion of patients with RA treated with biological agents (% of estimated RA population)
7.710.312.314.9